as on October 21, 2025 at 1:29 am IST
Day's Low
Day's High
1.76%
Downside
2.97%
Upside
52 Week's Low
52 Week's High
26.08%
Downside
62.03%
Upside
Check Actuate Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$173.9M
EPS (TTM)
-1.1475
Dividend Yield
0.00%
PE Ratio (TTM)
0PEG Ratio
0Return On Equity TTM
80948100.00%
Compare market cap, revenue, PE, and other key metrics of Actuate Therapeutics with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
NA | $173.9M | NA | NA | 0.00% | |
BUY | $63.1B | 259.92% | -505.15 | -12.96% | |
NA | $35.3B | NA | NA | -3.89% | |
BUY | $106.9B | 98.27% | 29.67 | 31.86% | |
BUY | $61.3B | 0.76% | 14.58 | 31.37% |
The Actuate Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Actuate Therapeutics investment value today
Current value as on today
₹1,09,102
Returns
₹9,102
(+9.1%)
Returns from Actuate Therapeutics Stock
₹4,372 (+4.37%)
Dollar Returns*
₹4,730 (+4.73%)
Search interest for Actuate Therapeutics Stock has decreased by -60% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 64.9% return, outperforming this stock by 59.4%
Price Dip
In the last 7 days, ACTU stock has moved down by -7.5%
Organisation | Actuate Therapeutics |
Headquarters | 1751 River Run, Fort Worth, TX, United States, 76107 |
CEO | Mr. Daniel M. Schmitt |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Mr. Paul J. Lytle CPA | Chief Financial Officer |
Dr. Alan Kozikowski Ph.D. | Scientific Founder and Advisor |
Mr. Daniel M. Schmitt | CEO, President & Director |
Dr. Andrew P. Mazar Ph.D. | Co-Founder & COO |
Actuate Therapeutics share price today is $7.4 as on at the close of the market. Actuate Therapeutics share today touched a day high of $7.62 and a low of $7.27.
Actuate Therapeutics share touched a 52 week high of $11.99 on and a 52 week low of $5.47 on . Actuate Therapeutics stock price today i.e. is closed at $7.4,which is 38.28% down from its 52 week high and 35.28% up from its 52 week low.
Actuate Therapeutics market capitalisation is $0.00T as on .
Indian investors can start investing in Actuate Therapeutics (ACTU) shares with as little as ₹87.9 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹879.00 in Actuate Therapeutics stock (as per the Rupee-Dollar exchange rate as on ).
Based on Actuate Therapeutics share’s latest price of $7.4 as on October 21, 2025 at 1:29 am IST, you will get 1.3514 shares of Actuate Therapeutics. Learn more about
fractional shares .